|
|
|
Insider
Information: |
Mueller Peter |
Relationship: |
Director |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
311,837 |
|
Indirect Shares
|
25,571 |
|
|
Direct
Value |
$67,267,974 |
|
|
Indirect Value
|
$11,948,817 |
|
|
Total
Shares |
337,408 |
|
|
Total
Value |
$79,216,791 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Global R&D, CSO |
2014-06-16 |
143,517 |
2014-06-16 |
25,571 |
Premium* |
|
Bioxcel Therapeutics Inc |
BTAI |
Director |
2019-08-23 |
168,320 |
2018-12-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
141 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VRTX |
Vertex Pharmaceuticals In... |
EVP Drug Innov.& Realiz, CSO |
|
2008-12-15 |
4 |
OE |
$9.07 |
$21,768 |
D/D |
2,400 |
88,790 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Drug Innov.& Realiz, CSO |
|
2009-01-15 |
4 |
OE |
$9.07 |
$21,768 |
D/D |
2,400 |
88,790 |
0 |
- |
|
BTAI |
Bioxcel Therapeutics Inc |
Director |
|
2019-08-23 |
4 |
B |
$9.34 |
$14,514 |
D/D |
1,554 |
168,320 |
2.39 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Drug Innov.& Realiz, CSO |
|
2009-02-17 |
4 |
OE |
$9.69 |
$23,256 |
D/D |
2,400 |
99,756 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Drug Innov.& Realiz, CSO |
|
2009-03-16 |
4 |
OE |
$9.69 |
$23,256 |
D/D |
2,400 |
99,756 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Drug Innov.& Realiz, CSO |
|
2009-04-15 |
4 |
OE |
$9.69 |
$23,256 |
D/D |
2,400 |
132,070 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Global R&D, CSO |
|
2009-05-15 |
4 |
OE |
$9.69 |
$23,256 |
D/D |
2,400 |
119,274 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Global R&D, CSO |
|
2009-06-15 |
4 |
OE |
$9.69 |
$23,256 |
D/D |
2,400 |
119,274 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Global R&D, CSO |
|
2009-07-15 |
4 |
OE |
$9.69 |
$23,256 |
D/D |
2,400 |
119,274 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Global R&D, CSO |
|
2009-12-04 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
118,474 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Global R&D, CSO |
|
2010-01-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
118,474 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-02-16 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
127,105 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-03-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
127,105 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-04-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
127,105 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-05-17 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-06-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-07-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-08-16 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-09-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-10-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-11-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-11 |
4 |
OE |
$10.41 |
$638,025 |
D/D |
40,000 |
173,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-15 |
4 |
OE |
$10.41 |
$26,025 |
D/D |
2,500 |
136,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-05-16 |
4 |
OE |
$10.41 |
$26,025 |
D/D |
2,500 |
136,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-06-15 |
4 |
OE |
$10.41 |
$26,025 |
D/D |
2,500 |
136,235 |
0 |
- |
|
141 Records found
|
|
Page 2 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|